Raia Drogasil S.A. (BVMF:RADL3)
Brazil · Delayed Price · Currency is BRL | Market Cap | 39.19B +18.1% |
| Revenue (ttm) | 44.25B +13.8% |
| Net Income | 1.30B +8.1% |
| EPS | 0.78 +10.0% |
| Shares Out | 1.75B |
| PE Ratio | 28.68 |
| Forward PE | 22.54 |
| Dividend | 0.39 (1.75%) |
| Ex-Dividend Date | Apr 7, 2026 |
| Volume | 4,900,200 |
| Average Volume | 9,752,495 |
| Open | 22.21 |
| Previous Close | 22.43 |
| Day's Range | 21.72 - 22.22 |
| 52-Week Range | 12.81 - 27.42 |
| Beta | 0.20 |
| RSI | 38.97 |
| Earnings Date | May 5, 2026 |
About Raia Drogasil
Raia Drogasil S.A. engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics and specialty medicines in Brazil. The company sells its products through stores, telesales, and call centers. Raia Drogasil S.A. was founded in 1905 and is headquartered in São Paulo, Brazil. [Read more]
Financial Performance
In 2025, Raia Drogasil's revenue was 44.25 billion, an increase of 13.84% compared to the previous year's 38.87 billion. Earnings were 1.30 billion, an increase of 8.08%.
Financial StatementsNews
Raia Drogasil Earnings Call Transcript: Q4 2025
Record Q4 2025 results with 23% retail growth, 170 bps market share gain, and strong digital expansion. Divested 4Bio for BRL 700 million to focus on core retail, while GLP-1 drugs and digital channels drove performance.
Raia Drogasil Earnings Call Transcript: Q3 2025
Q3 2025 saw robust revenue and EBITDA growth, driven by strong retail and digital performance, improved cost control, and record market share. Inventory and cash cycle improvements, new distribution centers, and digital expansion position the company for continued growth.
Raia Drogasil Earnings Call Transcript: Q2 2025
Strong sales and digital growth drove a 12% revenue increase and record net income, with market share gains across all regions. Inventory and expense efficiencies improved margins, while digital and retail segments both delivered robust performance.
Raia Drogasil Earnings Call Transcript: Q1 2025
1Q25 results missed expectations due to calendar and one-off effects, with sales up 10.8% and EBITDA margin down to 6%. Market share increased, digital sales grew 40%, and cost controls plus targeted promotions are underway to offset margin pressures.
Raia Drogasil Earnings Call Transcript: Q4 2024
2024 saw strong revenue and digital growth, with 300 new stores and market share gains, but Q4 was impacted by weak cosmetics sales and margin pressures from tax and mix effects. 2025 will focus on organic expansion, digital, and efficiency to offset regulatory and macroeconomic headwinds.
Raia Drogasil Earnings Call Transcript: Q3 2024
Q3 saw record revenue, margin expansion, and robust digital growth, with 72 new stores opened and strong free cash flow. Market share and customer satisfaction remain high, and management expects continued margin gains and expansion into Q4.
Raia Drogasil Earnings Call Transcript: Q2 2024
Q2 2024 saw 15.4% revenue growth to BRL 10.4 billion, with digital sales up 44% and mature stores outpacing inflation. Gross margin was pressured by regulatory changes, but strong expansion, customer loyalty, and digital investments drove market share gains and robust profitability.